TXA127 is a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.
Tarix Pharma expects to recruit a total of 74 patients at eight US medical centers.
The company has received US Food and Drug Administration (FDA) approval as a treatment to enhance engraftment in patients receiving a stem cell transplant.
Tarix Pharma CEO Rick Franklin said TXA127 has the potential to reduce the time it takes for blood cell counts to return to safe levels following stem cell transplant, which may accelerate the recovery process and reduce some of the health risks associated with stem cell transplant.
"TXA127 is unique because it directly stimulates transplanted stem cells to replenish circulating platelets, white blood cells, and red blood cells," Franklin said.